6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Male genitourinary schistosomiasis-related symptoms among long-term Western African migrants in Spain: a prospective population-based screening study

      research-article
      1 , 2 , 3 , , 1 , 2 , 4 , 1 , 1 , 2 , 2 , 1 , 2 , 1 , 2 , 3 , 1 , 2 , 3 , 5 , 6 , 7 , 5 , 6 , 1 , 1 , 8 , 9 , 9 , 10 , 1 , 2 , 3 , 11 , 2 , 3 , 11 , 11 , 12 , 11 , 2 , 13 , 14 , The Schisto-Stop study group
      Infectious Diseases of Poverty
      BioMed Central
      Schistosomiasis, Chronic schistosomiasis, Urogenital schistosomiasis, Male genital schistosomiasis, Long-term migrant

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Schistosomiasis is highly endemic in sub-Saharan Africa and frequently imported to Europe. Male urogenital manifestations are often neglected. We aimed to ascertain the prevalence of genitourinary clinical signs and symptoms among long-term African migrants in a non-endemic European country using a serology test.

          Methods

          We carried out a prospective, community-based cross-sectional study of adult male migrants from sub-Saharan Africa living in Spain. Schistosoma serology tests and microscopic urine examinations were carried out, and clinical data were obtained from an electronic medical record search and a structured questionnaire.

          Results

          We included 388 adult males, mean age 43.5 years [Standard Deviation ( SD) = 12.0, range: 18–76]. The median time since migration to the European Union was 17 [Interquartile range (IQR): 11–21] years. The most frequent country of origin was Senegal ( N = 179, 46.1%). Of the 338, 147 (37.6%) tested positive for Schistosoma. Parasite eggs were present in the urine of only 1.3%. Nine genitourinary clinical items were significantly associated with positive Schistosoma serology results: pelvic pain (45.2%; OR = 1.57, 95% CI: 1.0–2.4), pain on ejaculation (14.5%; OR = 1.85, 95% CI: 1.0–3.5), dyspareunia (12.4%; OR = 2.45, 95% CI: 1.2–5.2), erectile dysfunction (9.5%; OR = 3.10, 95% CI: 1.3–7.6), self-reported episodes of infertility (32.1%; OR = 1.69, 95% CI: 1.0–2.8), haematuria (55.2%; OR = 2.37, 95% CI: 1.5–3.6), dysuria (52.1%; OR = 2.01, 95% CI: 1.3–3.1), undiagnosed syndromic STIs (5.4%), and orchitis (20.7%; OR = 1.81, 95% CI: 1.0–3.1). Clinical signs tended to cluster.

          Conclusions

          Urogenital clinical signs and symptoms are prevalent among male African long-term migrants with a positive Schistosoma serology results. Genital involvement can be frequent even among those with long periods of non-residence in their sub-Saharan African countries of origin. Further research is needed to develop diagnostic tools and validate therapeutic approaches to chronic schistosomiasis.

          Graphical Abstract

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s40249-024-01190-8.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

          Summary Background How long one lives, how many years of life are spent in good and poor health, and how the population’s state of health and leading causes of disability change over time all have implications for policy, planning, and provision of services. We comparatively assessed the patterns and trends of healthy life expectancy (HALE), which quantifies the number of years of life expected to be lived in good health, and the complementary measure of disability-adjusted life-years (DALYs), a composite measure of disease burden capturing both premature mortality and prevalence and severity of ill health, for 359 diseases and injuries for 195 countries and territories over the past 28 years. Methods We used data for age-specific mortality rates, years of life lost (YLLs) due to premature mortality, and years lived with disability (YLDs) from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 to calculate HALE and DALYs from 1990 to 2017. We calculated HALE using age-specific mortality rates and YLDs per capita for each location, age, sex, and year. We calculated DALYs for 359 causes as the sum of YLLs and YLDs. We assessed how observed HALE and DALYs differed by country and sex from expected trends based on Socio-demographic Index (SDI). We also analysed HALE by decomposing years of life gained into years spent in good health and in poor health, between 1990 and 2017, and extra years lived by females compared with males. Findings Globally, from 1990 to 2017, life expectancy at birth increased by 7·4 years (95% uncertainty interval 7·1–7·8), from 65·6 years (65·3–65·8) in 1990 to 73·0 years (72·7–73·3) in 2017. The increase in years of life varied from 5·1 years (5·0–5·3) in high SDI countries to 12·0 years (11·3–12·8) in low SDI countries. Of the additional years of life expected at birth, 26·3% (20·1–33·1) were expected to be spent in poor health in high SDI countries compared with 11·7% (8·8–15·1) in low-middle SDI countries. HALE at birth increased by 6·3 years (5·9–6·7), from 57·0 years (54·6–59·1) in 1990 to 63·3 years (60·5–65·7) in 2017. The increase varied from 3·8 years (3·4–4·1) in high SDI countries to 10·5 years (9·8–11·2) in low SDI countries. Even larger variations in HALE than these were observed between countries, ranging from 1·0 year (0·4–1·7) in Saint Vincent and the Grenadines (62·4 years [59·9–64·7] in 1990 to 63·5 years [60·9–65·8] in 2017) to 23·7 years (21·9–25·6) in Eritrea (30·7 years [28·9–32·2] in 1990 to 54·4 years [51·5–57·1] in 2017). In most countries, the increase in HALE was smaller than the increase in overall life expectancy, indicating more years lived in poor health. In 180 of 195 countries and territories, females were expected to live longer than males in 2017, with extra years lived varying from 1·4 years (0·6–2·3) in Algeria to 11·9 years (10·9–12·9) in Ukraine. Of the extra years gained, the proportion spent in poor health varied largely across countries, with less than 20% of additional years spent in poor health in Bosnia and Herzegovina, Burundi, and Slovakia, whereas in Bahrain all the extra years were spent in poor health. In 2017, the highest estimate of HALE at birth was in Singapore for both females (75·8 years [72·4–78·7]) and males (72·6 years [69·8–75·0]) and the lowest estimates were in Central African Republic (47·0 years [43·7–50·2] for females and 42·8 years [40·1–45·6] for males). Globally, in 2017, the five leading causes of DALYs were neonatal disorders, ischaemic heart disease, stroke, lower respiratory infections, and chronic obstructive pulmonary disease. Between 1990 and 2017, age-standardised DALY rates decreased by 41·3% (38·8–43·5) for communicable diseases and by 49·8% (47·9–51·6) for neonatal disorders. For non-communicable diseases, global DALYs increased by 40·1% (36·8–43·0), although age-standardised DALY rates decreased by 18·1% (16·0–20·2). Interpretation With increasing life expectancy in most countries, the question of whether the additional years of life gained are spent in good health or poor health has been increasingly relevant because of the potential policy implications, such as health-care provisions and extending retirement ages. In some locations, a large proportion of those additional years are spent in poor health. Large inequalities in HALE and disease burden exist across countries in different SDI quintiles and between sexes. The burden of disabling conditions has serious implications for health system planning and health-related expenditures. Despite the progress made in reducing the burden of communicable diseases and neonatal disorders in low SDI countries, the speed of this progress could be increased by scaling up proven interventions. The global trends among non-communicable diseases indicate that more effort is needed to maximise HALE, such as risk prevention and attention to upstream determinants of health. Funding Bill & Melinda Gates Foundation.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Human schistosomiasis.

            Human schistosomiasis--or bilharzia--is a parasitic disease caused by trematode flukes of the genus Schistosoma. By conservative estimates, at least 230 million people worldwide are infected with Schistosoma spp. Adult schistosome worms colonise human blood vessels for years, successfully evading the immune system while excreting hundreds to thousands of eggs daily, which must either leave the body in excreta or become trapped in nearby tissues. Trapped eggs induce a distinct immune-mediated granulomatous response that causes local and systemic pathological effects ranging from anaemia, growth stunting, impaired cognition, and decreased physical fitness, to organ-specific effects such as severe hepatosplenism, periportal fibrosis with portal hypertension, and urogenital inflammation and scarring. At present, preventive public health measures in endemic regions consist of treatment once every 1 or 2 years with the isoquinolinone drug, praziquantel, to suppress morbidity. In some locations, elimination of transmission is now the goal; however, more sensitive diagnostics are needed in both the field and clinics, and integrated environmental and health-care management will be needed to ensure elimination. Copyright © 2014 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Spatial distribution of schistosomiasis and treatment needs in sub-Saharan Africa: a systematic review and geostatistical analysis.

              Schistosomiasis affects more than 200 million individuals, mostly in sub-Saharan Africa, but empirical estimates of the disease burden in this region are unavailable. We used geostatistical modelling to produce high-resolution risk estimates of infection with Schistosoma spp and of the number of doses of praziquantel treatment needed to prevent morbidity at different administrative levels in 44 countries.
                Bookmark

                Author and article information

                Contributors
                sroure@lluita.org
                Journal
                Infect Dis Poverty
                Infect Dis Poverty
                Infectious Diseases of Poverty
                BioMed Central (London )
                2095-5162
                2049-9957
                7 March 2024
                7 March 2024
                2024
                : 13
                : 23
                Affiliations
                [1 ]GRID grid.22061.37, ISNI 0000 0000 9127 6969, International Health Program (PROSICS), , Barcelona North Metropolitan Territorial Directorate for Infectious Diseases, Catalan Institute for Health, ; CAP La Salut, Passatge dels Encants S/N, 08916 Badalona, Spain
                [2 ]Fundació Lluita contra les Infeccions, ( https://ror.org/04xtz1057) c/ Can Ruti s/n, 08916 Badalona, Spain
                [3 ]Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol, ( https://ror.org/04wxdxa47) c/ Can Ruti s/n, 08916 Badalona, Spain
                [4 ]Germans Trias i Pujol Research Institute, c/ Can Ruti s/n, 08916 Badalona, Spain
                [5 ]GRID grid.411438.b, ISNI 0000 0004 1767 6330, Microbiology Department, , Germans Trias i Pujol University Hospital, ; c/ Can Ruti s/n, 08916 Badalona, Spain
                [6 ]Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, ( https://ror.org/052g8jq94) c/ Can Ruti s/n, 08916 Badalona, Spain
                [7 ]Faculty of Medicine, University of Asyut, ( https://ror.org/01jaj8n65) El Fateh, Assiut Governorate, 71515 Egypt
                [8 ]GRID grid.411438.b, ISNI 0000 0004 1767 6330, Department of Urology, , Germans Trias i Pujol University Hospital, ; c/ Can Ruti s/n, 08916 Badalona, Spain
                [9 ]GRID grid.22061.37, ISNI 0000 0000 9127 6969, Canovelles Primary Health Care Unit, , Barcelona North Metropolitan Health Directorate, Catalan Institute for Health, ; C/ Indústria 23, 08420 Canovelles, Spain
                [10 ]GRID grid.22061.37, ISNI 0000 0000 9127 6969, Primary Health Care Unit Mataró-3 (Rocafonda-Palau), Barcelona North Metropolitan Health Directorate, Catalan Institute for Health, ; Camí Ral el Ravalet 208, Mataró, 08302 Barcelona, Spain
                [11 ]GRID grid.22061.37, ISNI 0000 0000 9127 6969, Barcelona North Metropolitan Primary Care Directorate, Catalan Institute for Health, ; Ctra. de Barcelona 473, Sabadell, 08204 Barcelona, Spain
                [12 ]GRID grid.22061.37, ISNI 0000 0000 9127 6969, Directorate for Innovation and Interdisciplinary Cooperation, , Barcelona North Metropolitan Health Directorate, Catalan Institute for Health, ; C/ Can Ruti S/N, 08916 Badalona, Spain
                [13 ]IrsiCaixa-AIDS Research Institute, Hospital Universitari Germans Trias i Pujol University Hospital, ( https://ror.org/04wxdxa47) c/ Can Ruti s/n, 08916 Badalona, Spain
                [14 ]GRID grid.22061.37, ISNI 0000 0000 9127 6969, Infectious Diseases Directorate, , Barcelona North Metropolitan Health Directorate, Catalan Institute for Health, ; C/ Can Ruti S/N, 08916 Badalona, Spain
                Author information
                http://orcid.org/0000-0002-7982-0890
                Article
                1190
                10.1186/s40249-024-01190-8
                10919049
                38449032
                e5632f9c-971a-473d-bd33-c9b1ca6fad44
                © The Author(s) 2024

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 19 December 2023
                : 29 February 2024
                Funding
                Funded by: Fundació Lluita contra les Infeccions
                Categories
                Research Article
                Custom metadata
                © National Institute of Parasitic Diseases 2024

                schistosomiasis,chronic schistosomiasis,urogenital schistosomiasis,male genital schistosomiasis,long-term migrant

                Comments

                Comment on this article